New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 24, 2014
04:55 EDTSIAL, SIAL, SIAL, MMS, MMS, MMS, MD, MD, MD, MASI, MASI, MASI, LPNT, LPNT, LPNT, STE, STE, STE, XRAY, XRAY, XRAY, MRK, MRK, MRK, JNJ, JNJ, JNJCitigroup to host a conference
Global Healthcare Conference is being held in New York on February 24-26.
News For SIAL;MMS;MD;MASI;LPNT;STE;XRAY;MRK;JNJ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
June 25, 2015
10:39 EDTLPNTUniversal Health, HCA have most potential upside after ACA ruling, says Leerink
Subscribe for More Information
10:14 EDTLPNTHospital stocks jump after Supreme Court upholds 'Obamacare' subsidies
Subscribe for More Information
10:11 EDTLPNTACA tax subsidies upheld by Supreme Court
The decision of the Fourth Circuit was affirmed in King v. Burwell by a vote of 6 to 3, according to multiple media reports. The Supreme Court upholding the lower court ruling means that individuals who get health insurance through an exchange established by the federal government will be eligible for tax subsidies in all 50 states. Publicly traded companies in the health insurance space include Aetna (AET), Anthem (ANTM), Centene (CNC), Cigna (CI), Health Net (HNT), Humana (HUM), Molina Healthcare (MOH), UnitedHealth (UNH) and WellCare (WCG). Publicly traded companies in the hospital space include Community Health (CYH), HCA Holdings (HCA), LifePoint (LPNT), Tenet (THC) and Universal Health (UHS).
June 24, 2015
09:07 EDTMRKCAR-T cancer drug researchers seen as M&A targets, Bloomberg says
Juno Therapeutics (JUNO), Kite Pharma (KITE) and Bluebird Bio (BLUE) are trading well above their IPO levels as takeovers predictions have spurred interest and share increases for the developers of CAR-T gene therapies, said Bloomberg's "Real M&A" column, quoting Dimo Dimov, a professor at the University of Bath’s School of Management, as having said that companies such as Pfizer (PFE), Merck (MRK), Roche (RHHBY) and AstraZeneca (AZN) are "closely watching" the firms. Cellectis (CLLS), which is working with Pfizer on its own approach to CAR-T therapy, has said it wants to bring its therapy to market and doesn’t anticipate a sale, the report noted. Reference Link
08:48 EDTSTESteris discloses acquisition of General Econopak and Black Diamond Video
Subscribe for More Information
June 22, 2015
08:09 EDTMASIMasimo receives CE Mark for MightySat Rx pulse oximeter
Subscribe for More Information
06:37 EDTLPNTHealth insurers may change policies based on King v. Burwell ruling, NYT says
Subscribe for More Information
June 21, 2015
13:14 EDTMRKMerck shares could return 25%, Barron's says
Subscribe for More Information
June 19, 2015
14:37 EDTMMSMaximus amends by-laws separating CEO and president positions
On June 18 , the Board of Directors approved the amendment and restatement of the company’s by-laws. The Restated By-laws became effective immediately upon approval by the Board. The restated By-laws reflect the company’s separation of the CEO and President positions and clarify the respective powers and duties of the company’s CEO, its President and its VPs.
10:09 EDTLPNTFly Watch: Supreme Court may release key ACA decision soon
Subscribe for More Information
09:29 EDTLPNTLifePoint management to meet with Deutsche Bank
Subscribe for More Information
07:37 EDTLPNTSupreme Court decision on ACA suit due soon, says UBS
Subscribe for More Information
June 18, 2015
12:04 EDTMDMEDNAX management to meet with SunTrust
Meeting to be held in Boston on June 24 hosted by SunTrust.
09:39 EDTSTESteris expected to settle with FTC, agree to divestitures, CTFinancialNews says
Experts expect Steris will eventually agree to divest some operations of Synergy Health to allay Federal Trade Commission concerns and save its merger deal, said CTFinancialNews. Reference Link
07:53 EDTLPNTLifePoint management to meet with Deutsche Bank
Subscribe for More Information
June 17, 2015
17:00 EDTMRKOncoSec CEO expects 'to be in a better position to attract a strategic partner'
Subscribe for More Information
10:00 EDTMRKOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: AbbVie (ABBV) initiated with an Overweight at Piper Jaffray... Arista Networks (ANET) initiated with a Buy at Sterne Agee CRT... Astec (ASTE) initiated with a Buy at Maxim... Bristol-Myers (BMY) initiated with an Underweight at Piper Jaffray... Community Healthcare (CHCT) initiated with an Outperform at Oppenheimer... Eli Lilly (LLY) initiated with an Overweight at Piper Jaffray... Fitbit (FIT) initiated with a Buy ahead of IPO at Dougherty... Hortonworks (HDP) initiated with a Buy at Mizuho... II-VI (IIVI) initiated with a Buy at Benchmark Co.... J Sainsbury (JSAIY) initiated with an Underperform at Credit Suisse... McDermott (MDR) initiated with an Outperform at Cowen... Merck (MRK) initiated with a Neutral at Piper Jaffray... Molina Healthcare (MOH) initiated with a Buy at UBS... Pacific DataVision (PDVW) initiated with a Buy at Canaccord... Pfizer (PFE) initiated with an Overweight at Piper Jaffray... Quest Resource (QRHC) initiated with a Buy at Roth Capital... Regional Management (RM) initiated with a Buy at Janney Capital... Rofin-Sinar (RSTI) initiated with a Buy at Benchmark Co.... Salesforce (CRM) initiated with a Neutral at Exane BNP Paribas... Sprouts Farmers Markets (SFM) initiated with a Neutral at Cleveland Research... Tesco (TSCDY) initiated with an Underperform at Credit Suisse... WM Morrison (MRWSY) initiated with a Neutral at Credit Suisse... WWE (WWE) initiated with a Buy at BTIG... World Acceptance (WRLD) initiated with a Buy at Janney Capital... Zafgen (ZFGN) initiated with a Buy at SunTrust.
08:03 EDTMRKMerck Keytruda granted FDA orphan designation as gastric cancer treatment
The FDA granted Merck, Sharp & Dohme, a subsidiary of Merck, orphan status for Keytruda as a treatment of gastric cancer, including gastroesophageal junction adenocarcinoma. Reference Link
07:21 EDTJNJGeneric ADHD drugs still sold despite FDA non-equivalance finding, NYT reports
The FDA announced last November that two generic versions of Johnson & Johnson's (JNJ) Concerta ADHD drug, one made by Mallinckrodt (MNK) and the other by UCB, could no longer be considered the equivalent of the branded drug after tests and analyses suggested that their effectiveness began to wear off much more quickly, but the drugs are still being sold despite an FDA mandated deadline having passed for the companies to either prove the drugs were equivalent or remove them from the market, said The New York Times. The report noted a third generic product, sold by Actavis (AGN), was found to be equivalent to the branded Concerta. Reference Link
05:31 EDTMRKMerck initiated with a Neutral at Piper Jaffray
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use